No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ONTO Onto Innovation
- 197.010
- -6.330-3.11%
Close Jul 19 16:00 ET
- 197.800
- +0.790+0.40%
Post 18:55 ET
9.71BMarket Cap70.11P/E (TTM)
204.605High196.500Low483.04KVolume203.530Open203.340Pre Close95.79MTurnover0.99%Turnover Ratio80.09P/E (Static)49.28MShares238.93052wk High5.45P/B9.63BFloat Cap103.93552wk Low--Dividend TTM48.88MShs Float238.930Historical High--Div YieldTTM3.99%Amplitude0.800Historical Low198.299Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Shares of Companies Within the Broader Technology Sector Are Trading Lower Amid a Selloff in Chips and AI-related Stocks
Onto Innovation Down Over 12%, on Pace for Largest Percent Decrease Since March 2020 -- Data Talk
Onto Innovation, Inc. ( ONTO ) is currently at $209.14, down $28.91 or 12.14% --Would be lowest close since June 4, 2024, when it closed at $208.98 --On pace for largest percent decrease since March 1
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for
Stifel Maintains Onto Innovation(ONTO.US) With Buy Rating, Raises Target Price to $270
Stifel analyst Brian Chin maintains $Onto Innovation(ONTO.US)$ with a buy rating, and adjusts the target price from $240 to $270.According to TipRanks data, the analyst has a success rate of 76.9%
Analysts Conflicted on These Technology Names: Onto Innovation (ONTO) and Littelfuse (LFUS)
Express News | Onto Innovation Welcomes Stephen Schwartz to Its Board of Directors
Comments
Onto Innovation's declining ROCE trend is worrisome. Despite increased capital investment, returns and sales are dropping, possibly indicating a loss of competitive edge or market share. Despite poor fundamentals, investors remain hopeful due to significant stock growth in the past three years. However, if these trends persist, the company's long-term performance could suffer.
Returns On Capital Signal Tricky Times Ahead For Onto Innovation (NYSE:ONTO) 1
Onto Innovation Inc.'s high P/E ratio is worrying considering its lower predicted growth compared to the broader market. The current upbeat sentiment towards the company's stock may not last unless there's a substantial boost in its earnings growth.
Insiders selling shares of Onto Innovation Inc. slightly below current price could concern shareholders. Lack of recent insider transactions is neutral. 1.0% insider ownership suggests alignment with other shareholders. Yet, last 12 months' insider transactions are discouraging.
Observers warn falling returns may limit Onto Innovation's future growth even with apparent reinvestment. Despite strong stock performance, they suggest monitoring company earnings to see if investments pay off.
$Adtalem Global Education(ATGE.US$ $Beneficient(BENF.US$ $Ebix Inc(EBIX.US$ $Emergent BioSolutions(EBS.US$ $EnerSys(ENS.US$ $ESGL Holdings(ESGL.US$ $FutureFuel(FF.US$ $IonQ Inc(IONQ.US$ $Maxeon Solar Technologies(MAXN.US$ $MercadoLibre(MELI.US$ $Macrogenics(MGNX.US$ $Novo-Nordisk A/S(NVO.US$ $Onto Innovation(ONTO.US$ $Oracle(ORCL.US$ $Pagaya Technologies(PGY.US$ $Xtant Medical(XTNT.US$
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg